

Lipeon Therapeutics – investment opportunity

Martin Fusek

IOCB TTO




The Opportunity

- Novel drug for type 2 diabetes
- Unique mechanism
- Follow up indications
- Develop to phase IIa and align to Major Pharma

- To Invest 20 mil € in tranches
- To bring the value of the company to 200 mil € during the exit after 5 years
- Expected ROI : 400%

Target

- Type 2 diabetes market




- Other indications obesity, neurodegeneration

How

- To incorporate the company
- To finish preclin studies
- To prepare the IND
- To accomplish to phase I
- To accomplish to phase IIa
- Exit via acquisition from a big Pharma
- A variant of earlier alignment with Pharma is also considered

Technology

- Neuropeptide normally produced and acting in brain – part of the overall normal regulation of food intake - decreasing food intake/weight via its receptor.



Technology – lipidization of the molecule



- Lipidization allows **peripheral** s.c. application
- Lipidization increases the plasma stability
- Peripheral application allows regulation of multiple receptors

- Results – **glucose** levels, food intake, fat tissue = all **decrease**.





How do we differ ?

- Different Mechanism of action
- Slower offset of lowering of the food intake
- Safety






Proof of concept









Proof of concept



Proof of concept



Proof of concept



Financials





Fig. 1 Risk-adjusted NPVs for LipR31 sales. Risk-adjusted NPV for LipR31 project by phase, pre-money valuation shown. Partnering = finished Phase 2a.

Item (\$m)	2026	2027	2028	2029	2030	2031	2032	2033	2034
Total inflows	-5	30	313	494	730	883	1 018	1 152	1 167

Freedom to operate, IP status

- 3 patent applications covering different indications
- One of them already granted in Australia
- Other in national or PCT phases
- Not aware of any IP related issues

Team

- Experienced entrepreneur Hans Derksen – CEO
- Experienced CSO – Sonia Poli
- Expert in clin. Development – CMO – Roman Dvořák
- Experts for ADME/TOX and CMC – Stanley Roberts and Russ Blacher
- Principal investigator – Lenka Maletinska
- Interim CEO – Martin Fusek